Background/Aims: The molecular etiology of childhood acute lymphoblastic leukemia (ALL) is likely to involve interactions between environmental factors and genetic make up. Understanding these interactions between various predisposing genes for the risk of developing childhood leukemia is of considerable importance. CYP2E1 is a susceptible gene in this respect, especially for its capacity to bioactivate many procarcinogens including benzene and N-nitrosodimethylamine. The CYP2E1 gene possesses several polymorphisms in humans, and among them, CYP2E1*5B and *6 have been shown to be associated with increased risks of several chemical-induced diseases. There are limited and contradictory data on the association between the CYP2E1*5B variant allele and childhood ALL, and none on such associations of CYP2E1*6 and*7B variant alleles. The aim of this study was to investigate the possible association of CYP2E1*5B, *6 and *7B alleles, alone or in combination, with the risk of incidence of childhood ALL in a Turkish population. Methods: The genotypes for both polymorphisms were determined by polymerase chain reaction/restriction fragment length polymorphism techniques on 207 healthy controls and 168 patients. Results: Neither locus was associated with the occurrence of childhood ALL. On the other hand, when both CYP2E1*5B and *6 alleles were considered together, the risk of childhood ALL increased significantly (2.9-fold; OR = 2.9, 95% CI 1.0–8.5; p < 0.05). Moreover, the presence of at least 2 variant alleles of any combination increased the risk significantly 3.9 times, suggesting a combined effect (OR = 3.9, 95% CI 1.4–11.0). Conclusion: Individuals carrying combinations of CYP2E1*5B, *6 and *7B variants together are likely associated with the risk of developing childhood ALL.

Keywords:
Childhood acute lymphoblastic leukemia, Genetic polymorphism, Risk assessment, CYP2E1 gene
1.
Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004:350:1535–1548.
2.
Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, Sinnet D: polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002:8:802–810.
3.
Nebert DW, McKinnon RA, Puga A: Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996:15:273–280.
4.
Krajinovic M, Sinnet H, Richer C, Labuda D, Sinnet D: Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 2002:97:230–236.
5.
Pakakasama S, Mukda E, Sasanakul W, Kadegasem P, Udomsubpayakul U, Thithapandha A, Hongeng S: Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am J Hematol 2005:79:202–205.
6.
Arinç E, Philpot RM: Preparation and properties of partially purified pulmonary cytochrome P-450 from rabbits. J Biol Chem 1976:25:3213–3220.
7.
Guengerich FP, Kim DH, Iwasaki M: Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991:4:168–179.
8.
Kharasch ED, Thummel KE: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993:79:795–807.
9.
Guengerich FP: Human cytochrome P450 enzymes; in de Montellano O (ed): Cytochrome P450. New York, Plenum Publishers, 1995, pp 473–535.
10.
Koop DR, Casazza JP: Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. J Biol Chem 1985:260:13607–13612.
11.
Johansson I, Ingelman-Sundberg M: Benzene metabolism by ethanol-, acetone-, and benzene-inducible cytochrome P-450 (IIE1) in rat and rabbit liver microsomes. Cancer Res 1988;48:5387–5390.
12.
Arinç E, Adali O, Gencler-Ozkan AM: Induction of N-nitrosodimethylamine metabolism in liver and lung by in vivo pyridine treatments of rabbits. Arch Toxicol 2000;74:329–334.
13.
Arinç E, Adali O, Gençler-Özkan AM: Stimulation of aniline, p-nitrophenol and N-nitrosodimethylamine metabolism in kidney by pyridine treatments of rabbits. Arch Toxicol 2000;74:527–532.
14.
Hong J-Y, Pan J, Gonzales FJ, Gelboin HV, Yang CS: The induction of a specific form of cytochrome P-450 (P-450j) by fasting. Biochem Biophys Res Commun 1987;142:1077–1083.
15.
Song BJ, Matsunaga T, Hardwick JP, Park SS, Veech RL, Yang CS, Gelboin HV, Gonzales FJ: Stabilization of cytochrome P450j messenger ribonucleic acid in the rat. Mol Endocrinol 1987;1:542–547.
16.
Arinç E, Arslan S, Adali O: Differential effects of diabetes on CYP2E1 and CYP2B4 proteins and associated drug metabolizing enzyme activities in rabbit liver. Arch Toxicol 2005;79:427–433.
17.
Arinç E, Arslan S, Bozcaarmutlu A, Adali O: Effects of diabetes on rabbit kidney and lung CYP2E1 and CYP2B4 expression and drug metabolism and potentiation of carcinogenic activity of N-nitrosodimethylamine in kidney and lung. Food Chem Toxicol 2007;45:107–118.
18.
Ross D: Functions and distribution of NQO1 in human bone marrow: potential clues to benzene toxicity. Chem Biol Interact 2005;153–154:137–146.
19.
Lieber CS: Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997:77:517–543.
20.
Bolt HM, Roos PH, Thier R: The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 2003;76:174–185.
21.
Hayashi S, Watanabe J, Kawajiri K: Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIEI gene. J Biochem 1991;110:559–565.
22.
Vodicka P, Soucek P, Tates AD, Dusinska M, Sarmanova J, Zamecnikova M, Vodickova L, Koskinen M, Zwart FA, Natajaran AT, Hemminki K: Association between genetic polymorphisms and biomarkers in styrene-exposed workers. Mutat Res 2001;482:89–103.
23.
Fairbrother A, Grove J, de Waziers I, Steimel DT, Day CD, Crespi CL, Daly AK: Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998;8:543–552.
24.
Infante-Rivard C, Krajinovic M, Labuda D, Dinnet D: Childhood acute lymphoblastic leukemia associated with parental alcohol consumption and polymorphisms of carcinogen-metabolizing genes. Epidemiology 2002;13:277–281.
25.
Canalle R, Burim RV, Tone LG, Takahashi CS: Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 2004;43:100–109.
26.
Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, Spitz MR: Cytochrome P450 2E1 DraI polymorphism in lung cancer in minority populations. Cancer Epidemiol Biomark Prev 1998;7:13–18.
27.
Yang B-M, O’Reilly DA, Demaine AG, King-north AN: Study of polymorphisms in the CYP2E1 gene in patients with alcoholic pancreatitis. Alcohol 2001:23:91–97.
28.
Garte S, Gaspari L, Alexandrie A-K, Ambrosone C, Autrup H, Autrup JI, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmöller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell’Omo M, Dolzana V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsich L-L, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, Lieshout EMM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WHM, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shileds PG, Sim E, Sinhet D, Strange RC, Stücker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239–1248.
29.
Ulusoy G, Arinç E, Adali O: CYP2E1 genotyping in Turkish population: determination of CYP2E1*5B, *6 and *7B alleles. Drug Metab Rev 2005;37(suppl 2):349.
30.
Ulusoy G, Arinç E, Adali O: Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population. Arch Toxicol DOI: 10.1007/s00204-007-0200-y.
31.
El-Zein R, Zwischenbergher JB, Wood TG, Abdel Rahman SZ, Brekelbaum C, Au WW: Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 1997;381:189–200.
32.
Kongruttanachok N, Sukdikul S, Setavarin S, Kerekhjanarong V, Supiyaphun P, Voravud N, Poovorawan Y, Mutirangura A: Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. BMC Cancer 2001;1:4–8.
33.
Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF: Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1 and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomark Prev 1998;7:1013–1018.
34.
Liu S, Park JY, Schantz SP, Stern JC, Lazarus P: Elucidation of CYP2E1 5′ regulatory RsaI/PstI allelic variants and their role in risk for oral cancer. Oral Oncol 2001;37:437–445.
35.
Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, Lau AF: Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggests cell type specificities to tobacco carcinogens. Cancer Res 1998;58:4858–4863.
36.
Shields PG, Ambrosone CB, Graham S, Bowman ED, Harrington AM, Gillenwater KA, Marshall JR, Vena JE, Laughlin R, Nemoto T, Freudenheim JL: A cytochrome P4502E1 genetic polymorphism and tobacco smoking in breast cancer. Mol Carcinogen 1996;17:144–150.
37.
Farker K, Lehmann MH, Oelschlagel B, Haerting J, Hoffmann A, Janitzky V, Schubert J: Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp Toxicol Pathol 1998;50:425–431.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.